Open Orphan #ORPH – MHRA approval for nasal COVID-19 vaccine clinical trial
First in human trials for vaccine candidate with the potential to confer long-term immunity Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials, announces the first in human (Phase I) study of Codagenix intranasal SARS-CoV-2 […]
Pharma Tech Article – Open Orphan #ORPH – Accelerated Vaccine Development with Human Challenge Studies
Pharma Tech Article – Open Orphan #ORPH – Accelerated Vaccine Development with Human Challenge Studies Pharmaceutical companies worldwide are joining global efforts to combat, diagnose, treat and prevent infections from COVID-19. As we have seen, the search for vaccines and possible treatment to curb the transmission and reduce the mortality and morbidity produced by the virus […]
Open Orphan #ORPH subsidiary Venn Life Sciences wins two new contracts
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce its subsidiary Venn Life Sciences (“Venn”) has been awarded two new contracts. The first contract, which will commence immediately, is a COVID-19 […]
Open Orphan #ORPH – Directors Change
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce the appointment of Elaine Sullivan as a Non-Executive Director to the Board of Open Orphan. Elaine is a business leader and senior […]
Open Orphan #ORPH – Collaboration Agreement with HIC-VAC and Wellcome Trust
Open Orphan, a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce that its subsidiary hVIVO has been selected to lead a consortium, on behalf of HIC-Vac, an international network of researchers who are developing human […]
Open Orphan #ORPH Announces New £2.5m Influenza Challenge Study Contract Win
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce the signing of a £2.5 million contract by hVIVO, a subsidiary of Open Orphan, to conduct an Influenza human challenge study with […]
Open Orphan #ORPH – New 2-year contract with a tier 1 German pharmaceutical company
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce a new 2-year contract with a tier 1 German pharmaceutical company which is one of Europe’s top research-driven pharmaceutical companies. The contract guarantees […]
Open Orphan #ORPH / hVIVO Signs Contract with UK Government for the Development of a COVID-19 Human Challenge Study Model
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company, which is the world leader in the testing of vaccines and antivirals using human challenge studies, is pleased to announce the signing of a contract by hVIVO, a subsidiary of Open Orphan, with the UK Government to develop a COVID-19 (SARS-CoV-2) human challenge […]
Open Orphan #ORPH – Interim Results for 6 months ended 30 June, will be operationally profitable in Q4
Open Orphan Plc, a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical studies is pleased to announce its interim results for the six months ended 30 June 2020. The interim results include the first six months of hVIVO group (“hVIVO”) following its […]
Open Orphan #ORPH – New £4.3m Challenge Study Contract Win with Global Top 10 Vaccine Company
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce a new £4.3 million contract to conduct a human viral challenge study utilising one of our 8 traditional challenge study models for another […]